This is in accord with reports of exenatide use in patients with type 2 diabetes (43, 44), but the reduction in CRP was not seen in a previous study with PCOS patients (22); however, baseline CRP was measured using different methods between the two studies and cannot be compared, though our patients had a higher level of triglycerides (4.4 vs. 1.16 nmol/L) that may explain the significant reduction. Here, CRP is linked to polycystic ovary syndrome.